← 홈

흑색종 · HER2

8개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 8개
ADCCBiologicEli Lilly and CompanyPhase 2

Abemaciclib (Abemaciclib)

Advanced Cancer; Metastatic Melanoma · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 32.9%임상시험 77상태 RECRUITING
CGTBiologicMerck Sharp & Dohme LLCPhase 3

Recombinant Interferon Alfa-2b (Recombinant Interferon Alfa-2b)

Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8 · HER2

#HER2#CGT#Phase3#인기#세포유전치료+5
임상시험 63상태 ACTIVE
AntibodystaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Dose Escalation Doublet: Combination of NKTR-214 + nivolumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 64%임상시험 1상태 ACTIVE
AntibodystaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 64%임상시험 1상태 ACTIVE
AntibodystaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 64%임상시험 1상태 ACTIVE
AntibodystaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 64%임상시험 1상태 ACTIVE
AntibodystaleXencor, Inc.Phase 1

XmAb®23104 (XmAb®23104)

Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma · HER2

#HER2#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 1

ipilimumab (Yervoy®, Yervoy® (ipilimumab))

Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma · HER2

#HER2#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 ACTIVE